ESSA Pharma (EPIX) Raised to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) from a hold rating to a buy rating in a research report released on Tuesday. Zacks Investment Research currently has $0.25 price target on the stock.

According to Zacks, “ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. “

A number of other brokerages also recently weighed in on EPIX. ValuEngine upgraded shares of ESSA Pharma from a strong sell rating to a sell rating in a report on Friday, February 2nd. Bloom Burton upgraded shares of ESSA Pharma from a hold rating to a buy rating in a report on Thursday, January 18th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $4.63.

Shares of ESSA Pharma (EPIX) opened at $0.22 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of -1.32. ESSA Pharma has a fifty-two week low of $0.15 and a fifty-two week high of $3.59.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last posted its quarterly earnings data on Monday, December 11th. The company reported ($0.09) earnings per share (EPS) for the quarter. equities research analysts forecast that ESSA Pharma will post -0.29 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit